Collaboration to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet® dispensing technology, following consultation with FDA Chronic dry eye estimated to be a $5 billion global addressable market NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that it has entered into a collaboration agreement with Senju Pharmaceutical Co., Ltd.

2024年7月23日，在与美国食品和药物管理局（FDA）咨询慢性干眼症（估计为50亿美元的全球可寻址市场）后，合作重点开发Senju的SJP-0035配方，用于Eyenovia的Optejet®配药技术。Eyenovia，Inc.（纳斯达克：EYEN），一家商业阶段的眼科公司，拥有两种FDA批准的产品和儿科进行性近视的晚期资产，今天宣布已与Senju Pharmaceutical Co.，Ltd.签订合作协议。

(Senju), under which both companies intend to work to develop Senju’s corneal epithelial wound healing candidate, SJP-0035, for use with Eyenovia’s Optejet® dispensing technology, as a potential treatment for chronic dry eye disease. Per the terms of the agreement, Eyenovia and Senju are planning to meet with the U.S.

（Senju），两家公司都打算开发Senju的角膜上皮伤口愈合候选物SJP-0035，用于Eyenovia的Optejet®配药技术，作为慢性干眼症的潜在治疗方法。根据协议条款，Eynovia和Senju计划与美国会面。

Food and Drug Administration (FDA) to present a clinical development proposal that, if successful, could support a New Drug Application (NDA) filing for a novel drug-device combination product for the treatment of chronic dry eye disease. Nearly sixteen million Americans suffer from dry eye, with the cost of treatments totaling over $3 billion in the U.S.

美国食品和药物管理局（FDA）提出一项临床开发建议，如果成功，可以支持新药申请（NDA）申请一种用于治疗慢性干眼症的新型药物-器械组合产品。。

alone, and $5 billion globally. SJP-0035 as an eye drop has been shown in prior Phase 1 and Phase 2 studies to be well tolerated at multiple doses tested in over 250 subjects. A planned Phase 2b trial would evaluate SJP-0035 administered in the Optejet dispenser. “We are very pleased to further leverage our proprietary Optejet platform through this collaboration agreement with Senju, a global leader in eye care that has been part of the Eyenovia family since our inception,” stated Michael Rowe, chief executive officer of Eyenovia.

仅此一项，全球就有50亿美元。先前的1期和2期研究表明，SJP-0035作为一种滴眼剂，在250多名受试者中进行了多次剂量测试，耐受性良好。计划的2b期试验将评估在Optejet分配器中施用的SJP-0035。Eyenovia首席执行官迈克尔·罗（Michael Rowe）表示：“我们很高兴通过与Senju的合作协议，进一步利用我们专有的Optejet平台，Senju是全球眼科护理领导者，自我们成立以来一直是Eyenovia家族的一部分。”。

“Symptoms of dry eye can interfere signifi.

“干眼症的症状可能会严重干扰。